中药鼻敏方治疗过敏性鼻炎:双盲双模拟随机对照试验方案
针对肺脾气虚型过敏性鼻炎患者,设计双盲双模拟随机对照试验,比较鼻敏方与左西替利嗪的疗效与安全性。计划纳入80例,1:1随机分组,治疗4周随访12周,主要结局为鼻症状总分变化,并探索细胞因子与肠道菌群机制。
要点
- 肺脾气虚型过敏性鼻炎患者是鼻敏方的主要目标人群。
- 采用双盲双模拟设计,对照药为左西替利嗪,主要结局为鼻症状总分变化。
- 同时检测血清细胞因子和粪便肠道菌群,探索中药作用机制。
核心结论
- 该试验旨在为鼻敏方治疗肺脾气虚型过敏性鼻炎提供疗效与安全性证据,并探索其肠道菌群相关机制。
研究设计与样本
- 双盲、双模拟、随机对照试验,计划纳入80例肺脾气虚型过敏性鼻炎患者,1:1随机分入鼻敏方组或对照组。
主要发现
- 尚未报告试验结果,方案预设主要结局为鼻症状总分(TNSS)变化。
关键数值与推荐
- 鼻敏方组口服鼻敏方及左西替利嗪模拟剂,对照组口服左西替利嗪及鼻敏方模拟剂。
- 治疗4周,随访12周,随访期间每月记录TNSS、RQLQ(S)和VAS。
- 次要结局包括RQLQ(S)、VAS评分变化,血清IL-4、IFN-γ、TGF-β1、IL-17水平变化及粪便肠道菌群组成变化。
- 血和粪便样本于基线和治疗结束时采集,细胞因子用酶联免疫吸附法检测,肠道菌群用16S rRNA测序检测。
临床怎么用
- 为临床使用鼻敏方治疗肺脾气虚型过敏性鼻炎提供随机对照证据,并提示关注肠道菌群机制。
局限性
- 原文为试验方案,尚未报告结果,样本量80例,结论需待试验完成后确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with allergic rhinitis (AR) often seek help from Chinese medicine due to dissatisfaction with conventional treatments. Lung-spleen qi deficiency syndrome (LSQDS) is the most common type of AR, and the Chinese herbal medicine formula bi min fang (BMF) is commonly prescribed for AR patients with LSQDS. However, direct evidence supporting its efficacy and safety is not available, and its potential mechanism of action remains unclear. METHODS/DESIGN: This paper presents a double-blind, double-dummy, randomized controlled trial. After a 2-week run-in period, 80 AR patients with LSQDS will be recruited and randomly allocated to the BMF group or the control group in a 1:1 ratio. The patients in the BMF group will receive BMF and the placebo for levocetirizine hydrochloride orally, while the control group participants will receive levocetirizine hydrochloride and the placebo for BMF orally. All participants will receive 4 weeks of treatment and 12 weeks of follow-up. The primary outcome is a change in the Total Nasal Symptom Score (TNSS). Secondary outcomes include changes in scores for the standard version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S)), and visual analog scale (VAS); changes in serum levels of the cytokines interleukin-4, interferon-γ, transforming growth factor β-1, and interleukin-17; and changes in the gut microbiota composition in the stool. The TNSS, RQLQ(S), and VAS will be recorded at the beginning of, middle of and after the treatment period and at the end of each month in the 3-month follow-up period. Blood and stool samples will be collected at baseline and the end of the treatment. The aforementioned four cytokines will be detected in the serum using enzyme-linked immunosorbent assays, and the stool gut microbiota will be detected using 16S ribosomal ribonucleic acid sequencing. Any side effects of the treatment will be recorded. DISCUSSION: The results of this trial will provide consolidated evidence of the effect of BMF on AR and the potential mechanism by which BMF acts. This study will be the first to explore the mechanism of action of Chinese herbal medicine on the gut microbiota in AR. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR-IPR-17010970 . Registered on 23 March 2017.
引用
- Luo Q, Zhou S, Li X, et al. Chinese herbal medicine bi min fang for allergic rhinitis: protocol for a double-blind, double-dummy, randomized controlled trial. Trials. 2019. PMID: 30658660. doi:10.1186/s13063-018-3151-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。